Influenza Vaccine Reduces Risk of Adverse Cardiovascular Events in High-Risk Patients
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2014 Feb 1;89(3):224-225.
Does the influenza vaccine lower the risk of major adverse cardiovascular events in adults with coronary disease?
This meta-analysis found that the influenza vaccine is associated with a significantly lower risk of major adverse cardiovascular events in adults with coronary disease. The benefit of influenza vaccination is strongest in adults with a history of recent acute coronary syndrome within the previous six months (number needed to treat [NNT] = 8). (Level of Evidence = 1a)
These investigators searched multiple sources, including Medline, Embase, the Cochrane Register, reference lists of eligible articles, clinicaltrials.gov, and conference abstracts without language restrictions for all
POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for "Poem of the Week" or go to http://goo.gl/3niWXb.
Want to use this article elsewhere? Get Permissions